Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M4,466Revenue (TTM) $M1,222Net Margin (%)-2.1Altman Z-Score4.1
Enterprise Value $M4,402EPS (TTM) $-0.1Operating Margin %-6.0Piotroski F-Score6
P/E(ttm)--Beneish M-Score-1.8Pre-tax Margin (%)-6.0Higher ROA y-yY
Price/Book2.010-y EBITDA Growth Rate %--Quick Ratio1.7Cash flow > EarningsY
Price/Sales3.45-y EBITDA Growth Rate %--Current Ratio1.8Lower Leverage y-yY
Price/Free Cash Flow534y-y EBITDA Growth Rate %--ROA % (ttm)-0.9Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-1.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M558ROIC % (ttm)-0.9Gross Margin Increase y-yN

Gurus Latest Trades with OPK

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

OPK is held by these investors:



OPK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FROST PHILLIP MD ET ALCEO & Chairman, 10% Owner 2017-04-19Buy15,000$7.49-0.27view
FROST PHILLIP MD ET ALCEO & Chairman, 10% Owner 2017-04-18Buy27,800$7.262.89view
FROST PHILLIP MD ET ALCEO & Chairman, 10% Owner 2017-04-17Buy13,600$7.48-0.13view
FROST PHILLIP MD ET ALCEO & Chairman, 10% Owner 2017-04-13Buy30,800$7.58-1.45view
FROST PHILLIP MD ET ALCEO & Chairman, 10% Owner 2017-04-11Buy18,000$7.49-0.27view
FROST PHILLIP MD ET ALCEO & Chairman, 10% Owner 2017-04-10Buy33,000$7.6-1.71view
FROST PHILLIP MD ET ALCEO & Chairman, 10% Owner 2017-04-07Buy28,000$7.58-1.45view
FROST PHILLIP MD ET ALCEO & Chairman, 10% Owner 2017-04-06Buy28,600$7.58-1.45view
FROST PHILLIP MD ET ALCEO & Chairman, 10% Owner 2017-04-05Buy44,500$7.69-2.86view
FROST PHILLIP MD ET ALCEO & Chairman, 10% Owner 2017-04-04Buy7,400$7.69-2.86view

Press Releases about OPK :

Quarterly/Annual Reports about OPK:

News about OPK:

Articles On GuruFocus.com
Weekly CEO Buys Highlights Apr 10 2017 
Insiders Roundup: Apollo Global Management, Apple Apr 07 2017 
Weekly CEO Buys Highlight Apr 03 2017 
ChromaDex Appoints Steven D. Rubin, J.D., to its Board of Directors Mar 28 2017 
OPKO Receives FDA Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disor Mar 22 2017 
OPKO Health's GeneDx to have Significant Presence at ACMG 2017 Mar 14 2017 
OPKO Health to Participate in the Barclays Global Healthcare Conference Mar 14 2017 
OPKO Receives EU Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disord Mar 08 2017 
OPKO Subsidiary GenPath Women’s Health Announces the Availability of ClariTest™ Mar 07 2017 
Weekly CEO Buys Highlights Mar 06 2017 

More From Other Websites
Xenetic Biosciences’ PolyXen™ Platform Technology Accepted for Poster Presentation at the 13th... Apr 20 2017
3 Beaten-Up Healthcare Stocks: Are They Bargains? Apr 19 2017
ETFs with exposure to OPKO Health, Inc. : April 17, 2017 Apr 17 2017
Xenetic Biosciences Expands Executive Management Team with Appointment of James F. Parslow, MBA, CPA... Apr 04 2017
OPKO Health, Inc. :OPK-US: Earnings Analysis: 2016 By the Numbers : March 30, 2017 Mar 30 2017
OPKO Health, Inc. breached its 50 day moving average in a Bullish Manner : OPK-US : March 29, 2017 Mar 29 2017
ChromaDex Appoints Steven D. Rubin, J.D., to its Board of Directors Mar 28 2017
3 Stocks That Could Double Your Money Mar 25 2017
Opko Gets Orphan Status for Genetic Disorder Drug Mar 22 2017
OPKO Receives FDA Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological... Mar 22 2017
OPKO Health's GeneDx to have Significant Presence at ACMG 2017 Mar 14 2017
OPKO Health to Participate in the Barclays Global Healthcare Conference Mar 14 2017
Better Buy: Myriad Genetics, Inc. vs. Opko Health, Inc. Mar 11 2017
Biotech's Rally in 2017 Stumbles on Pricing Concerns: Today's Research Reports on Opko Health and... Mar 09 2017
OPKO Health (OPK) Launches Prenatal Testing Tool ClariTest Mar 08 2017
OPKO Receives EU Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological... Mar 08 2017
Opko Health subsidiary launches prenatal testing tool Mar 07 2017
OPKO Health, Inc. :OPK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
OPKO Subsidiary GenPath Women’s Health Announces the Availability of ClariTest™ Mar 07 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)